SBIR-STTR Award

Enzyme induction in freshly isolated human hepatocytes
Award last edited on: 9/6/06

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$95,765
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Andrew Parkinson

Company Information

XenoTech LLC

1101 West Cambridge Circle Drive
Kansas City, KS 66103
   (913) 438-7450
   info@xenotechllc.com
   www.xenotechllc.com
Location: Single
Congr. District: 03
County: Wyandotte

Phase I

Contract Number: 1R43GM074348-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2006
Phase I Amount
$95,765
This is Phase I of an SBIR grant application. The overall goal of this project is to enable the pharmaceutical industry to conduct high-throughput screening (HTS) studies with Fa2N-4 cells, a new cell line created by immortalizing human hepatocytes with SV-40 virus, in order to identify those drug candidates that will likely cause clinically significant drug-drug interactions as a result of their ability to induce (up-regulate) the expression of cytochrome P450 (CYP) and other drug-metabolizing/transporting enzymes. Enzyme induction by drugs and other agents (such as herbal agent St. John's Wort) is a serious cause of drug-drug interactions; it is responsible for the loss of therapeutic effect of life-saving drugs (such as anti-HIV, anti-cancer and anti-coagulant drugs) and life- modifying drugs (such as oral contraceptive steroids). The US-FDA now considers enzyme induction to be an obstacle to drug approval (i.e., grounds for disapproval), especially for drugs intended for use in combination with anti-HIV or other drugs used to treat life-threatening diseases. Enzyme induction occurs in a highly species-specific manner, such that studies aimed at assessing clinical outcome must be conducted in a human-based system. Currently, the use of primary cultures of human hepatocytes represents the "gold standard" for evaluating enzyme-induction potential in vitro, but this approach is limited by an inadequate (and erratic) supply of non-transplantable human liver. Human-derived hepatic cell lines, such as HepG2 cells, do not respond appropriately to those drugs that cause clinically significant enzyme induction because they lack a functional PXR/CAR signaling pathway. However, this signaling pathway is functional in the new line of immortalized human hepatocytes (Fa2N-4 cells), which suggests that these cells can be used to identify drug candidates as enzyme inducers, which will save millions of dollars in failed drug development costs, as well as improve drug safety by reducing the incidence of drug-drug interactions, which are reported to be one of the leading causes of adverse drug reactions (ADRs), which in turn are one of the leading causes of preventable death in the United States.

Thesaurus Terms:
cell line, cytotoxicity, drug discovery /isolation, drug interaction, enzyme induction /repression, high throughput technology, liver cell, technology /technique development biological signal transduction, cell biology, collagen, cryopreservation, cytochrome P450, drug metabolism, gene expression, karyotype, messenger RNA, nucleic acid quantitation /detection, pharmacokinetics, tissue /cell culture genetic screening, human genetic material tag

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----